Literature DB >> 30117023

Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.

Marios K Georgakis1, Georgios Tsivgoulis2,3, Dimitrios Spinos4, Nikolaos G Dimitriou4, Athanasios P Kyritsis5, Ulrich Herrlinger6, Eleni Th Petridou4,7.   

Abstract

INTRODUCTION: Gliomatosis cerebri (GC) is a rare fatal widespread infiltrating CNS tumor. As consistent disease features have not been established, the tumor comprises a diagnostic challenge.
METHODS: We conducted a systematic literature search for published case reports and case series on patients with histologically confirmed GC. Clinical, diagnostic, neuroimaging, histopathological, and molecular data on individual or summary patient level were extracted and analyzed.
RESULTS: A total of 274 studies were identified, including 866 patients with individual-level data and 782 patients with summary data (58.9% males, mean age 43.6 years). Seizures (49.8%) were the most common presenting symptom followed by headache (35.9%), cognitive decline (32.2%), and focal motor deficits (32%). Imaging studies showed bilateral hemisphere involvement in 65%, infratentorial infiltration in 29.9% and a focal contrast-enhanced mass (type II GC) in 31.1% of cases. MRI (extensive hyperintensities in T2/FLAIR sequences) and MR spectroscopy (elevated choline, creatinine, and myoinositol levels; decreased NAA levels) showed highly consistent findings across GC patients. Low-grade and anaplastic astrocytoma were the most prevalent diagnostic categories, albeit features of any histology (astrocytic, oligodendroglial, oligoastrocytic) and grade (II-IV) were also reported. Among molecular aberrations, IDH1 mutation and MGMT promoter methylation were the most commonly reported. Increasing time elapsed from symptom onset to diagnosis comprised the only independent determinant of the extent of CNS infiltration.
CONCLUSION: A distinct clinical, neuroimaging, histopathological, or molecular GC phenotype is not supported by current evidence. MRI and MR spectroscopy are important tools for the diagnosis of the tumor before confirmation with biopsy.

Entities:  

Keywords:  Brain tumor; Clinical features; Diagnostics; Glioma; Gliomatosis cerebri

Mesh:

Year:  2018        PMID: 30117023     DOI: 10.1007/s11060-018-2976-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Value of diagnosis and differential diagnosis of MRI and MR spectroscopy in gliomatosis cerebri.

Authors:  Aihong Yu; Kuncheng Li; Hongli Li
Journal:  Eur J Radiol       Date:  2006-08       Impact factor: 3.528

Review 2.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

3.  Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.

Authors:  Sophie Taillibert; Catherine Chodkiewicz; Florence Laigle-Donadey; Massimo Napolitano; Stéphanie Cartalat-Carel; Marc Sanson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  Incidence and survival of gliomatosis cerebri: a population-based cancer registration study.

Authors:  Marios K Georgakis; Dimitrios Spinos; Apostolos Pourtsidis; Amanda Psyrri; Ioannis G Panourias; Spyridon Sgouros; Eleni Th Petridou
Journal:  J Neurooncol       Date:  2018-02-20       Impact factor: 4.130

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

6.  NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

Authors:  Martin Glas; Oliver Bähr; Jörg Felsberg; Katja Rasch; Dorothee Wiewrodt; Martin Schabet; Matthias Simon; Horst Urbach; Joachim P Steinbach; Johannes Rieger; Rolf Fimmers; Michael Bamberg; Thomas Nägele; Guido Reifenberger; Michael Weller; Ulrich Herrlinger
Journal:  Ann Neurol       Date:  2011-06-27       Impact factor: 10.422

7.  MR spectroscopy in gliomatosis cerebri.

Authors:  M Bendszus; M Warmuth-Metz; R Klein; R Burger; C Schichor; J C Tonn; L Solymosi
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

8.  1H MR spectroscopy in the assessment of gliomatosis cerebri.

Authors:  Juan A Guzmán-de-Villoria; Javier Sánchez-González; Lucia Muñoz; Santiago Reig; Carlos Benito; Pedro García-Barreno; Manuel Desco
Journal:  AJR Am J Roentgenol       Date:  2007-03       Impact factor: 3.959

9.  Gliomatosis cerebri: clinical characteristics, management, and outcomes.

Authors:  Selby Chen; Shota Tanaka; Caterina Giannini; Jonathan Morris; Elizabeth S Yan; Jan Buckner; Daniel H Lachance; Ian F Parney
Journal:  J Neurooncol       Date:  2013-01-23       Impact factor: 4.130

10.  Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Authors:  Ulrich Herrlinger; David T W Jones; Martin Glas; Elke Hattingen; Dorothee Gramatzki; Moritz Stuplich; Jörg Felsberg; Oliver Bähr; Gerrit H Gielen; Matthias Simon; Dorothee Wiewrodt; Martin Schabet; Volker Hovestadt; David Capper; Joachim P Steinbach; Andreas von Deimling; Peter Lichter; Stefan M Pfister; Michael Weller; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2015-10-22       Impact factor: 17.088

View more
  2 in total

1.  Leber's hereditary optic neuropathy with diffuse white matter changes mimicking gliomatosis cerebri: illustrative case.

Authors:  Wakiko Saruta; Ichiyo Shibahara; Hajime Handa; Madoka Inukai; Shunsuke Kanayama; Ryoma Yasumoto; Keizo Sakurai; Hisanao Akiyama; Hitoshi Ishikawa; Sumito Sato; Takuichiro Hide; Toshihiro Kumabe
Journal:  J Neurosurg Case Lessons       Date:  2021-06-28

2.  A rare case of gliomatosis cerebri lurking beneath the shadows of a stroke mimic.

Authors:  Apoorv Prasad; Gage Hurlburt; Emily Van Antwerp; Samiksha Srivastava; Shitiz Sriwastava
Journal:  Radiol Case Rep       Date:  2021-07-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.